Poll

Poll results: Will you use biosimilars in your ophthalmic practice?

Results from our recent poll indicate that many ophthalmologists (63%) plan to use biosimilars in their clinical practice.

Ophthalmology Times® polled our audience with the following question from September 26, 2022 to October 10, 2022:​ Will you use biosimilars in your ophthalmic practice?

The poll appeared on OphthalmologyTimes.com and was promoted in our e-newsletters during this time. Results show a majority of ophthalmologists plan to use biosimilars in their practice.

37 responses were recorded, in total. Of these:

23% responded, "Yes, I plan to use biosimilars in my practice."

14% responded, "No, I do not plan to use biosimilars in my practice."

.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
© 2025 MJH Life Sciences

All rights reserved.